Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7292   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    356 result(s) found for: Immunity. Displaying page 1 of 18.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-004406-42 Sponsor Protocol Number: FCO-TIM-2015-01 Start Date*: 2016-03-10
    Sponsor Name:FIBICO
    Full Title: CLINICAL TRIAL TO ASSEES THE NON-INFERIORITY OF THE SUSPENSION OF PROPHYLACTIC TREATMENT WITH VALGANCICLOVIR IN KIDNEY TRANSPLANT CMV-seropositive PATIENTS, WHO MANTEIN CD8+ CMV- CELLULAR IMMUNI...
    Medical condition: Kidney transplant cytomegalovirus-seropositive
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004541-33 Sponsor Protocol Number: immvzmpr1 Start Date*: Information not available in EudraCT
    Sponsor Name:Västra Götalandsregionen
    Full Title: A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer.
    Medical condition: This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated ...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002456-21 Sponsor Protocol Number: 74082 Start Date*: 2020-05-28
    Sponsor Name:Radboudumc
    Full Title: Enhancing the BCG-induced trained immunity response by addition of bisphosphonate or MMR vaccine: a possible preventive approach against COVID-19 (BCG-PLUS)
    Medical condition: Trained immunity COVID-19 This study will investigate whether oral bisphosphonate supplementation or the MMR vaccine can be used as immune potentiators when simultaneously administered with BCG, t...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001901-18 Sponsor Protocol Number: LGS.MMR.01.2016.2022 Start Date*: 2017-02-14
    Sponsor Name:The Danish National University Hospital "Rigshospitalet"
    Full Title: Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting
    Medical condition: Infection with measles, mumps or rubella
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10036654 Prevention LLT
    Population Age: Preterm newborn infants, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002928-41 Sponsor Protocol Number: Immunity_TBE Start Date*: 2013-01-14
    Sponsor Name:Med. Uni. Wien, Klinik für Innere I
    Full Title: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study
    Medical condition: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study Study group consists of patients 11...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002378-37 Sponsor Protocol Number: LIS/IMM138 Start Date*: 2008-12-23
    Sponsor Name:National Institute of Health and the Environment (RIVM)
    Full Title: The longitudinal kinetics of long term cellular memory immunity against Bordetella pertussis in Dutch 8-9 years old children after ACV booster vaccination.
    Medical condition: Whooping cough is a respiratory disease caused by Bordetella pertussis. Young infants are mostly at risk, but older children are the main source of infection. Since the incidence of whooping cough...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022703-22 Sponsor Protocol Number: MItrial Start Date*: 2011-01-03
    Sponsor Name:NKI-AVL
    Full Title: Local immunotherapy by the synergism of monobenzone and imiquimod cream (MI) for cutanous metastases in stage III-IV melanoma patients.
    Medical condition: patients with cutanous melanoma (stage III-IV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002088-23 Sponsor Protocol Number: DemiVac2021 Start Date*: 2021-05-05
    Sponsor Name:Sciensano
    Full Title: Covid-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population (REDU-VAC)
    Medical condition: Healthy persons from age 18 till age 56
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004099-31 Sponsor Protocol Number: 116811 Start Date*: 2016-07-26
    Sponsor Name:Glaxosmithkline Biologicals
    Full Title: Long-term persistence of immunity to hepatitis B in adults vaccinated 20 to 30 years ago with Engerix™-B.
    Medical condition: Healthy volunteers (immunisation against infection caused by all known subtypes of hepatitis B virus).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10019731 Hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003303-18 Sponsor Protocol Number: rl.01.2013 Start Date*: Information not available in EudraCT
    Sponsor Name:Gedeon Richter Polska Sp. z o. o.
    Full Title: Clinical phase IV study assessing the efficacy and safety of the medicinal product Groprinosin in treatment of recurrent airway inflammation in children with impaired cellular immunity and diagnose...
    Medical condition: Recurrent airway inflammation in children with impaired cellular immunity.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004231-24 Sponsor Protocol Number: TBEB13 Start Date*: 2013-03-05
    Sponsor Name:Department für Virologie, Medizinische Universität Wien
    Full Title: Long-term immunity after primary vaccination against tick-borne encephalitis in the elderly
    Medical condition: long-term B-cell immunity against tick-borne encephalitis (TBE) in healthy volunteers who have received 3-dose primary vaccination at an age between 18 and 31 years or older than 60 years.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000684-16 Sponsor Protocol Number: 03MI10 Start Date*: 2010-01-21
    Sponsor Name:Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health
    Full Title: Gene therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector.
    Medical condition: X-Linked severe combined Immunodeficiency (SCID-X1)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010099 Combined immunodeficiency LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001678-31 Sponsor Protocol Number: APHP200462 Start Date*: 2020-04-28
    Sponsor Name:Assistance Publique Hopitaux de Paris
    Full Title: Randomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Work...
    Medical condition: COVID 19 Health care workers (medical or non-medical) in French hospitals in direct contact with COVID-19 patients, including nurses, medical doctors and other personnel working in wards in charge...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001709-26 Sponsor Protocol Number: IMS012012 Start Date*: 2012-06-28
    Sponsor Name:Sevapharma,a.s.
    Full Title: Randomized, double-blind, placebo-controlled clinical trial of Immodin immunological efficacy in healthy adult volunteers.
    Medical condition: Immunological efficacy, in healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10021422 Immune status LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004419-14 Sponsor Protocol Number: T125/2020 Start Date*: 2021-10-18
    Sponsor Name:Turku University Hospital
    Full Title: COVID-19 infections in hospital personnel
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004891-33 Sponsor Protocol Number: T33/2021 Start Date*: 2022-04-13
    Sponsor Name:Turku University Hospital
    Full Title: COVID-19 vaccine induced immune response in patients with primary antibody deficiency
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020450-33 Sponsor Protocol Number: IX-senesc2.0 Start Date*: 2010-06-23
    Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine
    Full Title: Characterization of cellular and humoral immunity in the elderly upon vaccination with the purified inactivated Japanese Encephalitis Vaccine IXIARO®
    Medical condition: The aim of this project is to investigate humoral and cellular immune responses before and after immunisation with the Japanese encephalitis vaccine IXIARO in subjects above 65 years of age in comp...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10069544 Japanese encephalitis immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005800-24 Sponsor Protocol Number: version1.0 Start Date*: 2008-10-22
    Sponsor Name:Medizinische Universität Wien, Institut für Spezifische Prophylaxe und Tropenmedizin
    Full Title: Characterisation of humoral and cellular immunity of low- and high-responder after TBE vaccination
    Medical condition: The aim of this project is to investigate the humoral and cellular immune responses of low-responders after TBE vaccination in order to find parameters regarding immunoregulation against TBE. It is...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039244 Routine vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004978-16 Sponsor Protocol Number: V59P5E1 Start Date*: 2007-12-07
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months who Have Previously Received Novartis MenACWY Conjugate Vacc...
    Medical condition: Novartis Meningococcal ACWY Conjugate Vaccine is intended for prevention of meningitidis and septicemia caused by Neisseria meningitidis serogroups A, C, W-135 and Y.
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003573-42 Sponsor Protocol Number: 232100-0131 Start Date*: 2014-11-11
    Sponsor Name:Västra Götalandsregionen
    Full Title: Antibody-mediated immune response after immunization with FSME-Immun(R) against Tick Borne Encephalitis(TBE) after hematopoietic autologous and allogeneic stem cell transplantation.
    Medical condition: Patients have undergone allogeneic or autologous stem cell transplantation for hematological malignancies.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 06 21:10:18 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA